CompletedPhase 1

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Australia, Mexico94 participantsStarted 2023-05-09

Plain-language summary

This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants 18-65 years old, inclusive * BMI of 25 - 40, inclusive * Stable body weight for two months Additional Inclusion Criterion for Part 3 (MD T2DM cohorts) only: * Participants in Part 3 should have a documented diagnosis of Type 2 Diabetes Mellitus (T2DM) * Participants in Part 3 should have glycated hemoglobin (HbA1c) between 7.0% and 10.0% Exclusion Criteria: * History of significant medical conditions and malignancy * Uncontrollable hypertension * History of alcoholism or drug addiction within 1 year prior to Screening * Current or recent participation in an investigational clinical trial

What they're measuring

Incidence of Treatment-Emergent Adverse Events

Timeframe: From first study drug administration until last safety follow-up (up to 31 days [Part 1] or 58 days [Parts 2 and 3])

Trial details

NCT IDNCT05814107

SponsorCarmot Australia First Pty Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-11-07

View on ClinicalTrials.gov More Type 2 Diabetes trials